Handelsbanken Fonder AB Purchases 400 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Handelsbanken Fonder AB boosted its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 7.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,672 shares of the medical research company’s stock after acquiring an additional 400 shares during the period. Handelsbanken Fonder AB’s holdings in Bio-Rad Laboratories were worth $1,863,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Strategic Financial Concepts LLC bought a new position in Bio-Rad Laboratories during the fourth quarter valued at about $3,561,000. Lecap Asset Management Ltd. acquired a new stake in Bio-Rad Laboratories during the fourth quarter valued at approximately $510,000. Principal Financial Group Inc. boosted its holdings in Bio-Rad Laboratories by 95.6% during the third quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company’s stock valued at $14,836,000 after purchasing an additional 21,669 shares in the last quarter. Mawer Investment Management Ltd. boosted its holdings in Bio-Rad Laboratories by 63.0% during the third quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock valued at $72,900,000 after purchasing an additional 84,237 shares in the last quarter. Finally, Verition Fund Management LLC boosted its holdings in Bio-Rad Laboratories by 193.3% during the third quarter. Verition Fund Management LLC now owns 3,470 shares of the medical research company’s stock valued at $1,161,000 after purchasing an additional 2,287 shares in the last quarter. 65.24% of the stock is currently owned by institutional investors.

Bio-Rad Laboratories Stock Down 0.8 %

Shares of BIO opened at $277.81 on Wednesday. The company has a market capitalization of $7.78 billion, a P/E ratio of -4.27 and a beta of 0.90. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85. Bio-Rad Laboratories, Inc. has a one year low of $262.12 and a one year high of $387.99. The business’s 50 day simple moving average is $330.43 and its 200-day simple moving average is $333.76.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. As a group, sell-side analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Wells Fargo & Company decreased their price objective on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 12th. StockNews.com downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Finally, Citigroup lifted their price objective on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Bio-Rad Laboratories has a consensus rating of “Moderate Buy” and an average target price of $395.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.